FMP

FMP

Enter

ALNEV.PA - Neovacs S.A.

Financial Summary of Neovacs S.A.(ALNEV.PA), Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the tr

photo-url-https://financialmodelingprep.com/image-stock/ALNEV.PA.png

Neovacs S.A.

ALNEV.PA

EURONEXT

Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.

0.32 EUR

0.0298 (9.32%)

About

ceo

Mr. Hugo Brugiere M.Sc.

sector

Healthcare

industry

Biotechnology

website

https://www.neovacs.com

exchange

EURONEXT

Description

Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration an...

CIK

N/A

ISIN

FR001400MV37

CUSIP

F6520D111

Address

3-5, Impasse Reille

Phone

33 1 53 10 93 00

Country

FR

Employee

23

IPO Date

Apr 21, 2010

Summary

CIK

-

Exchange

EURONEXT

Industry

Biotechnology

Sector

Healthcare

CUSIP

F6520D111

ISIN

FR001400MV37

Country

FR

Price

0.32

Beta

-868.81

Volume Avg.

1.75M

Market Cap

101.97k

Shares

-

52-Week

1.0E-4-3.2

DCF

0

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

0

P/B

-

Website

https://www.neovacs.com

Historical Prices

We are unable to load the chart at this time.

fmp-logo

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

People Also Watch

page loading card

Latest ALNEV.PA News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep